BioLife Solutions, Inc. (NASDAQ:BLFS) Receives Consensus Rating of “Hold” from Brokerages

Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) have received a consensus recommendation of “Hold” from the five research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $32.00.

A number of research analysts have recently weighed in on the stock. Zacks Research downgraded shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioLife Solutions in a report on Monday, April 20th.

BioLife Solutions Stock Performance

Shares of BLFS opened at $28.11 on Friday. The firm has a market cap of $1.37 billion, a PE ratio of -351.33 and a beta of 1.94. The firm’s 50 day moving average price is $24.66 and its 200 day moving average price is $23.11. BioLife Solutions has a twelve month low of $17.86 and a twelve month high of $30.00.

BioLife Solutions (NASDAQ:BLFS) last posted its earnings results on Thursday, May 7th. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.03. The firm had revenue of $27.50 million during the quarter, compared to analysts’ expectations of $25.66 million. BioLife Solutions had a negative net margin of 2.80% and a positive return on equity of 1.81%. On average, sell-side analysts anticipate that BioLife Solutions will post 0.02 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other BioLife Solutions news, major shareholder Casdin Partners Master Fund, L sold 650,000 shares of the business’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $23.70, for a total value of $15,405,000.00. Following the completion of the sale, the insider owned 4,757,165 shares of the company’s stock, valued at $112,744,810.50. The trade was a 12.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 1,200,000 shares of company stock worth $28,125,000 in the last 90 days. 2.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On BioLife Solutions

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Global Retirement Partners LLC bought a new stake in BioLife Solutions during the fourth quarter worth approximately $30,000. Kemnay Advisory Services Inc. bought a new position in shares of BioLife Solutions in the fourth quarter valued at approximately $35,000. State of Wyoming bought a new position in shares of BioLife Solutions in the first quarter valued at approximately $52,000. Quarry LP lifted its stake in shares of BioLife Solutions by 50.9% in the third quarter. Quarry LP now owns 2,113 shares of the medical equipment provider’s stock worth $54,000 after buying an additional 713 shares during the last quarter. Finally, Hantz Financial Services Inc. lifted its stake in shares of BioLife Solutions by 42.4% in the fourth quarter. Hantz Financial Services Inc. now owns 2,673 shares of the medical equipment provider’s stock worth $65,000 after buying an additional 796 shares during the last quarter. 93.24% of the stock is currently owned by institutional investors and hedge funds.

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.